Stocks · News reference

Barclays Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $710

Aug 11, 2026, 1:51 PMBenzinga Newsdesk

Barclays analyst Glen Santangelo maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and lowers the price target from $800 to $710.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Globenewswire IncAug 25, 2026, 6:53 PMBcc Research
Global Veterinary Medical Devices Market to Reach $9.1 Billion by 2030, Driven by Rising Pet Ownership and Technological Innovation in Animal Healthcare
The global veterinary medical devices market is projected to grow from $6.5 billion in 2024 to $9.1 billion by 2030 at a 6.1% CAGR, driven by pet humanization trends, expanding pet insurance coverage, and AI-enabled diagnostic innovations. North America dominates with 55.9% market share, while emerging markets present long-term growth opportunities.
Read original at globenewswire-inc
IDXX ZTS MDT
BenzingaAug 11, 2026, 11:09 AMBenzinga Newsdesk
IDEXX Announces Launch Of Catalyst proBNP Test For Assessing Heart Disease In Cats And Dogs, Available In North America Beginning October 2026
Read original at benzinga
IDXX
BenzingaAug 5, 2026, 8:27 PMBenzinga Newsdesk
UBS Maintains Neutral on IDEXX Laboratories, Raises Price Target to $670
UBS analyst Andrea Alfonso maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and raises the price target from $620 to $670.
Read original at benzinga
IDXX